Filing Details

Accession Number:
0001209191-24-001805
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-01-17 19:03:36
Reporting Period:
2024-01-12
Accepted Time:
2024-01-17 19:03:36
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1679363 Morphic Holding Inc. MORF Pharmaceutical Preparations (2834) 473878772
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1773184 Marc Schegerin C/O Morphic Holding, Inc.
35 Gatehouse Drive, A2
Waltham MA 02451
Cfo And Coo No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2024-01-13 14,675 $0.00 38,811 No 4 M Direct
Common Stock Acquisiton 2024-01-14 4,690 $0.00 43,501 No 4 M Direct
Common Stock Disposition 2024-01-16 6,041 $27.49 37,460 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy Common Stock) Acquisiton 2024-01-12 133,200 $0.00 133,200 $27.79
Common Stock Restricted Stock Unit Acquisiton 2024-01-12 85,800 $0.00 85,800 $0.00
Common Stock Restricted Stock Unit Disposition 2024-01-13 14,675 $0.00 14,675 $0.00
Common Stock Restricted Stock Unit Disposition 2024-01-14 4,690 $0.00 4,690 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
133,200 2034-01-11 No 4 A Direct
85,800 No 4 A Direct
44,025 No 4 M Direct
9,380 No 4 M Direct
Footnotes
  1. Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the issuer's Common Stock upon settlement.
  2. The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
  3. The option vests as to 2.0833% of the total shares monthly, beginning February 12, 2024, with 100% of the total shares vested and exercisable on January 12, 2028, subject to the reporting person's provision of service to the issuer on each vesting date.
  4. The RSUs vest as to 25% of the total shares on each of January 12, 2025, January 12, 2026, January 12, 2027 and January 12, 2028, subject to the reporting person's provision of service to the issuer on each vesting date.
  5. The RSUs vest as to 25% of the total shares on each of January 13, 2024, January 13, 2025, January 13, 2026 and January 13, 2027, subject to the reporting person's provision of service to the issuer on each vesting date.
  6. The RSUs vest as to 25% of the total shares on each of January 14, 2023, January 14, 2024, January 14, 2025 and January 14, 2026, subject to the reporting person's provision of service to the issuer on each vesting date.